Advanced

2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe : Results from the I-MOVE+ project

Rondy, Marc ; Larrauri, A. ; Casado, I. ; Alfonsi, V. ; Pitigoi, D. ; Launay, O. ; Syrjänen, R. K. ; Gefenaite, G. LU ; Machado, A. and Vučina, V. V. , et al. (2017) In Eurosurveillance 22(30).
Abstract

We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI:... (More)

We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
publishing date
type
Contribution to journal
publication status
published
subject
in
Eurosurveillance
volume
22
issue
30
publisher
European Centre for Disease Prevention and Control (ECDC)
external identifiers
  • scopus:85027014121
  • pmid:28797322
ISSN
1025-496X
DOI
10.2807/1560-7917.ES.2017.22.30.30580
language
English
LU publication?
no
id
7c432257-9513-46ce-8b0d-b1172641592f
date added to LUP
2020-05-14 14:28:24
date last changed
2020-11-10 02:45:12
@article{7c432257-9513-46ce-8b0d-b1172641592f,
  abstract     = {<p>We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.</p>},
  author       = {Rondy, Marc and Larrauri, A. and Casado, I. and Alfonsi, V. and Pitigoi, D. and Launay, O. and Syrjänen, R. K. and Gefenaite, G. and Machado, A. and Vučina, V. V. and Horváth, J. K. and Paradowska-Stankiewicz, I. and Marbus, S. D. and Gherasim, A. and Díaz-González, J. A. and Rizzo, C. and Ivanciuc, A. E. and Galtier, F. and Ikonen, N. and Mickiene, A. and Gomez, V. and Kurečić Filipović, S. and Ferenczi, A. and Korcinska, M. R. and Van Gageldonk-Lafeber, R. and Valenciano, M. and Altzibar, Jone M. and Arraras, Ion Garcia and Cilla, Gustavo and Marco, Elisa and Vidal, Matxalen and Omenaca, Manuel and Castilla, J. and Navascues, A. and Ezpeleta, C. and Barrado, L. and Ortega, M. T. and Bella, A. and Castrucci, M. R. and Puzelli, S. and Chironna, M. and Germinario, C. and Ansaldi, F. and Orsi, A. and Manini, I. and Montomoli, E. and Lupulescu, E. and Lazar, M. and Cherciu, C. M. and Meijer, A.},
  issn         = {1025-496X},
  language     = {eng},
  month        = {07},
  number       = {30},
  publisher    = {European Centre for Disease Prevention and Control (ECDC)},
  series       = {Eurosurveillance},
  title        = {2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe : Results from the I-MOVE+ project},
  url          = {http://dx.doi.org/10.2807/1560-7917.ES.2017.22.30.30580},
  doi          = {10.2807/1560-7917.ES.2017.22.30.30580},
  volume       = {22},
  year         = {2017},
}